Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 18 or above~* Subjects in good general health.~* Females must have negative pregnancy test and be using adequate form of contraception~Exclusion Criteria:~* History of vaccination/infection with JE or Yellow fever or other flaviviruses~* History of residence/travel to flavivirus endemic regions~* History of anaphylaxis/serious adverse reactions~* Administration of vaccine within 30 days of study or during treatment period~* Clinically significant physical exam/medical history/lab abnormalities~* Pregnancy~* Excessive alcohol/drug abuse~* Hypersensitivity to constituents of JE-VAX®~* Blood transfusion/treatment with blood product within 6months of study and during study treatment period~* Known/suspected immunodeficiency~* Compromised blood brain barrier~* Employees of Clinical Research Organization (CRO)/study site staff~* Any other condition which would exclude subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ChimeriVax™-JE (Type: EXPERIMENTAL): Participants received dose each of saline placebo on Days 0 and 7. On Day 30, participants received vaccinations of ChimeriVax™-JE vaccine and saline placebo into different arms.
- JE-VAX® (Type: ACTIVE_COMPARATOR): Participants received 1 dose each of JE-VAX® vaccine on Days 0, 7, and 30, and a dose of saline placebo into a different arm on Day 30.

Based on this trial design, predict the completion outcome and termination type (if applicable).